Fig. 3: Epigenetic reactivation of pro-epithelial gene expression in MDA-MB-231 cells following treatment with CtBP inhibitors.
From: Epigenetic re-wiring of breast cancer by pharmacological targeting of C-terminal binding protein
a Diagram of CtBP ChIP-seq profile14 used to select amplicon regions for detecting CtBP occupancy at the proximal promoter and upstream regions of the GRHL2, FOXA1, GATA3, OVOL2, miRNA 203, and miRNA 200c genes. b qChIP profile of CtBP binding to the promoter and upstream regions of OVOL2, GATA3, FOXA1, GRHL2, miRNA 203, and miRNA 200c following treatment of MDA-MB-231 cells with the vehicle and 10 μM CI19, CI22, CI23, and CI24 inhibitors for 24 h prior to ChIP. c qRT-PCR profiles of BRCA1, FOXA1, CDH1, OVOL2, GATA3, and GRHL2 mRNA and miRNA 200c and miRNA 203 abundance in MDA-MB-231 cells treated 24 h with 10 μM CtBP inhibitors as indicated. d (Top), immuno-blot profiling of CtBP1 and CtBP2 in nuclear and cytoplasmic extracts of MDA-MB-231 treated 24 h with vehicle or 10 μM of the indicated CtBP inhibitors. (Bottom), immuno-blot profiling of BRCA1, GRHL2, FOXA1, GATA3, CDH1, OVOL2, and GAPDH protein expression in whole-cell lysates of MDA-MB-231 cells, treated as described above. The error bars represent the s.d. of the mean from at least two independent experiments. P-values are calculated from the Students to T-Test relative to the vehicle control. *Indicates P < 0.05 and **indicates P < 0.01
